Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and maintained a $9 price target.
June 17, 2024 | 9:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Autolus Therapeutics and maintained a $9 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst can boost investor confidence in Autolus Therapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100